SISAQOL-IMI Launches Final Recommendations to Enhance Patient-Reported Outcomes in Cancer Clinical Trials

Ghent, 5 February 2025 – SISAQOL-IMI (Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – IMI), an international multidisciplinary consortium co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI) and formed under the Innovative Medicines Initiative (IMI), hosted a public launch event on 4 February 2025 in Ghent, Belgium.

SISAQOL-IMI was convened in 2021 with the goal of achieving international consensus across stakeholders on the optimal methods of analysis of health-related quality of life (HRQOL) and patient-reported outcome (PRO) data in cancer clinical trials. Forty-one stakeholder groups were involved in the partnership, including researchers from the pharmaceutical industry, academia, non-profit associations, cancer institutes, regulators, and patient advocacy organisations. The aim of the project was to produce a set of recommendations for the use, analysis, and interpretation of PRO data in cancer clinical trials, ultimately helping healthcare providers, patients, researchers and policy makers make better-informed decisions considering the impact of treatment on patients’ lives.

The public launch included presentations from consortium members on the highlights of the final recommendations as well as presentations from select stakeholders on their implementation plans. A panel discussion also brought together representatives from several key stakeholder groups to discuss the measurable impact they would like to see as indicators of SISAQOL’s success in the coming years.

The project will continue until the end of 2025 with a focus on training, dissemination and sustainability. The final SISAQOL recommendations will ultimately be made fully accessible to the public through an interactive webtool on the SISAQOL website, along with supporting materials for implementation by patient partners and other stakeholders within 2025.

Further information can be found across our website.